**Original Paper**

**Sebaceous Carcinoma of the Breast: Report of Four Cases and Review of the Literature**

Marián Švajdler¹,²,³, Peter Baník¹, Katarína Poliaková⁴, Lubomír Straka⁴,
Zuzana Hribíková⁵, Zdeněk Kinkor⁵, Dmitry V. Kazakov¹,², Alena Skálová¹,²,
Michal Michal¹,²

¹Šík’s Department of Pathology, Charles University, Medical Faculty in Pilsen, Czech Republic
²Bioptická laboratoř, s.r.o., Pilsen, Czech Republic
³Department of Pathology, Louis Pasteur University Hospital, Košice, Slovakia
⁴Klinická patológia Prešov, s.r.o., Prešov, Slovakia
⁵HIS-DG, s.r.o., Košice, Slovakia

Sebaceous carcinoma of the breast is an exceedingly rare neoplasm. Little is known about the behavior and prognosis of this type of breast cancer. We report clinical, histological and immunohistochemical features of four cases of breast carcinoma with prominent (at least 50%) sebaceous differentiation. The tumors occurred in four women, aged 25-66, and were composed of cords, lobules and solid sheets of tumor cells with sebaceous differentiation, comprising 50-90% of the tumor mass. The second component consisted of cells with non-vacuolated cytoplasm, present mostly around the periphery of the lobules, or which formed separate tumor sheets with no evidence of sebaceous differentiation and were indistinguishable from a classical ductal carcinoma. Immunohistochemically, three tumors expressed hormone receptors; all cases were HER2-negative and had retained expression of the DNA mismatch repair proteins. Three patients had axillary lymph node metastases, and two patients had distant metastases: one in the liver, lung and bones, and one in the mediastinal and supraclavicular lymph nodes. One patient died 28 months after diagnosis, indicating that mammary sebaceous carcinoma is a potentially aggressive neoplasm. In contrast to extraocular cutaneous sebaceous carcinomas, mammary sebaceous carcinoma is probably unrelated to Muir-Torre syndrome. It should be differentiated from morphologically similar but biologically distinct lipid-rich carcinoma.

**Key words:** breast, sebaceous carcinoma, lipid-rich carcinoma, hormone receptors, HER2.

---

**Introduction**

Sebaceous differentiation in a mammary carcinoma is a very rare phenomenon. It has been described in 15 cases so far in the English-language literature, either as a minor or predominant component in a classical ductal carcinoma or as a pure line of differentiation [1-11]. According to the current WHO classification, primary sebaceous carcinoma of the breast must show sebaceous differentiation in at least 50% of cells and have no evidence of origin from the cutaneous adnexa [12]. Because of its rare occurrence, little is known about the behavior and prognosis of this type of breast cancer. We report clinical, histological and immunohistochemical features of four cases of breast carcinoma with prominent (at least 50%) sebaceous differentiation, and the literature on sebaceous differentiation in mammary tumors is reviewed.
Clinical history

Case 1

A 65-year-old woman presented during regular mammography checkup with an opaque mass lesion in the upper lateral quadrant of her right breast. The mass was a new finding and had not been present on the mammograms two years before. The lesion showed irregular borders and retraction of the surrounding parenchyma (BI-RADS 5); the skin was unremarkable. A quadrantectomy with sentinel lymph node sampling was performed, followed by an axillary lymph node dissection. Macroscopically, the tumor measured 16 mm, had a grayish and yellow cut surface and was localized 15 mm from the overlying skin. The sentinel lymph node showed a metastasis of the carcinoma with a sebaceous morphology. Thirty-two axillary lymph nodes were retrieved; two of them showed a metastasis with a sebaceous morphology and one lymph node showed a micrometastasis with a classical ductal morphology. The patient underwent chemotherapy (four cycles of doxorubicin + cyclophosphamide + four cycles of docetaxel) followed by radiotherapy (total dose 50.0 Gy). After the therapy she gave birth to one child. Currently, the patient is on hormonal (anti-estrogen) therapy with no evidence of disease 27 months after diagnosis.

Case 2

The patient was a 61-year-old woman. A routine mammography examination showed an asymmetry in the upper lateral quadrant of the right breast (BI-RADS 2). An ultrasonographic examination revealed a hypoechoic poorly circumscribed mass measuring 17 × 10 × 7 mm (BI-RADS 5) and a suspicious lymph node metastasis in the right axilla. The skin was inconspicuous. A modified radical mastectomy was performed. Grossly, the tumor was grayish-white on the cut surface and was poorly circumscribed. There was no connection to the overlying skin. An axillary lymphadenectomy yielded five lymph nodes; one lymph node showed a metastasis. The patient was treated postoperatively with six cycles of chemotherapy (fluorouracil + doxorubicin + cyclophosphamide), followed by tamoxifen. Twenty months after diagnosis, the patient underwent radical hysterectomy because of a well-differentiated endometrioid carcinoma. Regional recurrence of the breast cancer appeared 26 months after diagnosis and was treated by surgery, radiotherapy (total dose 50.0 Gy) and chemotherapy (6 cycles of vinorelbine + capecitabine). Disease progression occurred after another 28 months, with metastases in the mediastinal and supraclavicular lymph nodes. Eleven cycles of paclitaxel + bevacizumab were administered, followed by letrozole. She is in a good condition with a clinically stable disease, 70 months after diagnosis.

Case 3

A 66-year-old woman presented with a history of a palpable mass in the right breast. A modified radical mastectomy with axillary lymph node dissection was performed. Macroscopically, the tumor measured 30 mm in the largest diameter, showed a firm white cut section and had infiltrative borders. The skin above the tumor was unremarkable. One of ten lymph nodes showed a metastasis. The patient was treated postoperatively with six cycles of chemotherapy (fluorouracil + doxorubicin + cyclophosphamide), followed by 1.5 Gy. Twenty months after diagnosis, the patient underwent radical hysterectomy because of a well-differentiated endometrioid carcinoma. Regional recurrence of the breast cancer appeared 26 months after diagnosis and was treated by surgery, radiotherapy (total dose 50.0 Gy) and chemotherapy (6 cycles of vinorelbine + capecitabine). Disease progression occurred after another 28 months, with metastases in the mediastinal and supraclavicular lymph nodes. Eleven cycles of paclitaxel + bevacizumab were administered, followed by letrozole. She is in a good condition with a clinically stable disease, 70 months after diagnosis.

Case 4

A 25-year-old woman presented during regular medical checkup with a palpable lump in her right breast. Ultrasonographic and mammographic examination confirmed a tumor mass. Segmentectomy and axillary lymphadenectomy were performed. The cut surface of the tumor was brownish and white. The size of the tumor and number of lymph nodes examined are unknown (consultation case); however, all lymph nodes were free of metastases. Postoperatively, the patient received six cycles of chemotherapy (doxorubicin + cyclophosphamide) followed by radiotherapy (total dose 50.0 Gy) with a high-dose radiation (HDR) boost (15.0 Gy). After the therapy she gave birth to one child. Currently, the patient is on hormonal (anti-estrogen) therapy with no evidence of disease 75 months after diagnosis.

Clinical findings are summarized in Table I.

Material and methods

The tissue specimens were fixed in 10% buffered formalin, routinely processed and embedded in paraffin. Five-µm thick sections were stained with hematoxylin and eosin. Immunohistochemistry was done manually, according to the manufacturer’s protocols. The following antibodies were used: estrogen recep-
tor (clone 1D5, RTU, Dako, Glostrup, Denmark), progesterone receptor (clone PgR656, RTU, Dako, Glostrup, Denmark), Ki-67 (clone MM1, 1:50, Diagnostic Biosystems, Pleasanton, USA), p53 (clone D07, RTU, Dako, Glostrup, Denmark), HercepTest Dako (Dako, RTU, Glostrup, Denmark), EMA (clone E29, 1:100, Diagnostic Biosystems, Pleasanton, USA), S100 (clone 4C4.9, 1:100, Diagnostic Biosystems, Pleasanton, USA), GCDFP-15 (clone 23A3, 1:100, Cell Marque, Rocklin, USA), MLH1 (clone ES05, 1:100, Leica, Newcastle, UK), PMS2 (clone EPR3947, RTU, Cell Marque, Rocklin, USA), MSH2 (clone 25D12, 1:100, Leica, Newcastle, UK) and MSH6 (clone 44, 1:100, Diagnostic Biosystems, Pleasanton, USA). Appropriate positive and negative controls were used.

Results

Histologically, the tumors were composed of cords, lobules and solid sheets of cells with abundant vacuolated cytoplasm, reminiscent of mature sebocytes (Fig. 1). The sebaceous cell component varied from case to case, comprising 50-90% of the tumor volume. The nuclei of the sebaceous component varied from relatively small monomorphic and darkly stained, to large and pleomorphic with more vesicular appearance and prominent basophilic or slightly eosinophilic nucleoli. The nuclei were mostly eccentrically located and scalloped by the intracytoplasmic vacuoles (Fig. 2). The second component of the tumors consisted of cells with non-vacuolated eosinophilic or basophilic cytoplasm. These cells were present mostly around the periphery of the lobules but also were focally intermixed with sebaceous cells (Fig. 3) or formed separate tumor sheets with no evidence of sebaceous differentiation and were indistinguishable from a classical ductal carcinoma (Fig. 4). Foci of comedonecrosis in the sebaceous component were present in two cases (Fig. 5). One tumor showed foci of ductal carcinoma in situ with sebaceous differentiation (Fig. 6). Squamous differentiation was not seen. Mitotic activity ranged from 5 to 39 mitoses per 10 high power fields. The stroma was densely collagenous or slightly myxoid. Individual cords and small nests of tumor cells were separated by thin collagenous septa with a rich capillary network. Lymphovascular invasion was identified in three cases. Prominent retraction clefts mimicking lymphatic spread were present in one case. None of the tumors reached the dermis or showed pagetoid spread. Histological findings are summarized in Table II.

Immunohistochemically, three tumors expressed hormone receptors and one was completely negative. In the positive cases, estrogen (ER) and progesterone receptors (PR) were expressed in 90-100% and 5-80% of tumor cells, respectively. HER2 (HercepTest Dako) was negative (0 or 1+) in three cases and equivocally positive (2+) in one case; CISH analysis (performed in an external laboratory) did not show amplification of the HER2 gene. The Ki-67 labeling index, investigated in three cases, was 5%, 30% and 80%. One of the two investigated cases showed p53 overexpression (strong nuclear positivity in 30% of cells). EMA was expressed in three cases, whereas the remaining tumor was negative. S100 protein

<table>
<thead>
<tr>
<th>CASE</th>
<th>AGE</th>
<th>TUMOR LOCALIZATION</th>
<th>pTNM</th>
<th>THERAPY</th>
<th>FOLLOW-UP</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>65</td>
<td>right breast, upper lateral quadrant</td>
<td>T1c N1a M0</td>
<td>quadrantectomy + SLN + axillary dissection; ACT; RAT (42.56 Gy); letrozole</td>
<td>ANOD 27 months</td>
</tr>
<tr>
<td>2</td>
<td>61</td>
<td>right breast, upper lateral quadrant</td>
<td>T2 N1a M1</td>
<td>mastectomy + axillary dissection; FAC; RAT (50.0 Gy); paclitaxel + bevacizumab + bisphosphonates; gemcitabine + carboplatin</td>
<td>MTS in the liver, lungs and bone; pathological fracture of the femur; arrhythmia; DOD 28 months</td>
</tr>
<tr>
<td>3</td>
<td>66</td>
<td>right breast</td>
<td>T2 N1a M1</td>
<td>mastectomy + axillary dissection; FAC + tamoxifen; RAT (50.0 Gy) + vinorelbine + capecitabine; paclitaxel + bevacizumab + letrozole</td>
<td>endometrial carcinoma; local recurrence; mediastinal and supraclavicular lymph nodes MTS; AWD 70 months</td>
</tr>
<tr>
<td>4</td>
<td>25</td>
<td>right breast</td>
<td>Tx N0 Mx</td>
<td>segmentectomy + axillary dissection; AC + RAT (50.0 Gy) + HDR boost (15.0 Gy) + anti-estrogen</td>
<td>gave birth to one child; ANOD 75 months</td>
</tr>
</tbody>
</table>

SLN = sentinel lymph node biopsy; ACT = doxorubicin + cyclophosphamide + docetaxel; AC = doxorubicin + cyclophosphamide; FAC = fluorouracil + doxorubicin + cyclophosphamide; RAT = radiotherapy; HDR = high-dose radiation; MTS = metastases; ANOD = alive with no evidence of disease; AWD = alive with disease; DOD = dead of disease
Sebaceous carcinoma of the breast

Fig. 1. Sebaceous carcinoma: Lobules of tumor cells with abundant vacuolated cytoplasm. More basophilic tumor cells are present at the periphery of the lobules. The stroma is densely collagenous (case 4, HE, magnification 100×).

Fig. 2. Relatively uniform proliferation of cells with finely vacuolated cytoplasm and hyperchromatic scalloped nuclei without prominent nucleoli (case 1, HE, magnification 400×).

Fig. 3. Cells with non-vacuolated eosinophilic cytoplasm around the periphery of some nests. High-grade nuclear atypia and pleomorphism are more evident in these cells (case 1, HE, magnification 400×).

Fig. 4. Separate tumor sheets with no evidence of sebaceous differentiation, indistinguishable from a classical ductal carcinoma (case 1, HE, magnification 200×).

Fig. 5. Foci of comedonecrosis were present in two cases (case 3, HE, magnification 400×).

Fig. 6. Ductal carcinoma in situ with sebaceous features (case 1, HE, magnification 400×).
and GCDFP-15 expression were investigated in three and two cases, respectively; one tumor showed S100 expression; the rest of the cases were negative for these markers. All tumors had retained expression of the DNA mismatch repair proteins (MLH1, PMS2, MSH2 and MSH6). Immunohistochemical findings are summarized in Table III.

Discussion

Primary sebaceous carcinoma (SC) of the breast is a very rare tumor. It was proposed that SC represents a rare variant of metaplastic breast carcinoma [7, 11]. Carlucci et al. observed sebaceous differentiation in a triple-negative carcinoma with ductal, squamous, adenosquamous and spindle cell differentiation in the primary tumor and additional osteochondroid differentiation in the metastasis, respectively [11]. We have also observed sebaceous differentiation in a case of metaplastic high grade spindle cell carcinoma (unpublished personal observation, Z.K.). However, SC of the breast is classified in the current WHO classification as a separate entity along with other exceptionally rare types of carcinoma (i.e. secretory carcinoma, oncocytic carcinoma, lipid-rich carcinoma or glycogen-rich clear cell carcinoma). Sebaceous carcinoma is defined as a breast carcinoma with prominent sebaceous differentiation in at least 50% of cells and no evidence of origin from cutaneous adnexal sebaceous glands [12]. To the best of our knowledge, only ten cases of mammary SC are well documented in the English-language literature conforming to the above definition [1, 3-9]; these cases are summarized in Table IV. One of these cancers occurred in a male patient [3]. These tumors occurred in patients across a wide age range (25-85 years, including our cases). A few cases of invasive ductal carcinoma with a minor sebaceous component (i.e. < 50%) have also been described [2, 10, 11]. Moreover, sebaceous differentiation rarely occurs in other malignant and benign mammary lesions: adenoid cystic carcinoma [13], cylindroma [14], adenomyoepithelioma [15, 16] or intraductal papilloma [17]. We have also observed sebaceous differentiation in a distinct subset of breast tumors which, in our view, are poorly characterized in breast pathology. They often show areas reminiscent of adenoid cystic carcinoma and constantly manifest plentiful ductal structures lined by an eosinophilic cuticle [18].

Not much is known about the behavior and prognosis of mammary SC. Two reported cases showed metastasis in one regional lymph node [6, 8]; three cases had negative lymph nodes [3-5]. Follow-up is available in three cases only: one patient was alive with no evidence of disease 24 months after the operation [8]; the second patient had no evidence of disease after ten months [3]; the third patient had skin and bone metastases 132 months after surgery [5]. Follow-up of our cases indicates that mammary SC might be a high-grade malignant neoplasm. Three of four patients had axillary lymph node metastases and two patients experienced an aggressive clinical course with distant metastases: one with metastases to the liver, lung and bones, and one with metastases to the mediastinal and supraclavicular lymph nodes. The carcinoma in case 2 proved to be fatal, and this case represents the first documented fatal case of mammary SC.

Regarding the potential therapeutic targets in mammary SC, altogether six cases (including three present cases) were ER and PR-positive [3, 5, 6] and

<table>
<thead>
<tr>
<th>Case</th>
<th>Nuclear Grade (per 10 hpf)</th>
<th>Mitoses</th>
<th>Nottingham Histologic Grade</th>
<th>Sebaceous Component (%)</th>
<th>Lymphovascular Spread</th>
<th>Sebaceous DCIS</th>
<th>Comedo Necrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>15</td>
<td>3</td>
<td>80</td>
<td>+</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>39</td>
<td>3</td>
<td>50</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>7</td>
<td>2</td>
<td>&gt; 90</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>60</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

*hpF – high power fields; DCIS – ductal carcinoma in situ*

<table>
<thead>
<tr>
<th>Case</th>
<th>ER (%)</th>
<th>PR (%)</th>
<th>HER2</th>
<th>Ki-67 (%)</th>
<th>p53 (%)</th>
<th>GCDFP-15</th>
<th>S100</th>
<th>EMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>100</td>
<td>30</td>
<td>0</td>
<td>30</td>
<td>30</td>
<td>NA</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1+</td>
<td>80</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
<td>+</td>
</tr>
<tr>
<td>3</td>
<td>90</td>
<td>5</td>
<td>2+ / no HER2 amplification</td>
<td>5</td>
<td>NA</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>100</td>
<td>80</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

*NA – not available*
Sebaceous carcinoma of the breast

one case was ER-negative/PR-positive [4]. Three cases were hormone receptors-negative, including one of our cases [8, 9]. Three patients with ER/PR-positive tumors and available follow-up were alive with no evidence of disease, 10, 27 and 75 months after the operation (the case reported by Mazzella et al. [3] and cases 1 and 4 from the current report). Another two patients with hormone-positive tumors showed an aggressive clinical course with distant metastases, but were alive after 132 months and 70 months (the case reported by Varga et al. [5] and case 3 from the current study). One patient with ER/PR-negative tumor was alive with no evidence of disease 24 months after the operation [8], and one patient died 28 months after diagnosis (case 2 from the present study). All seven cases (including four present cases) that were investigated for HER2 expression/amplification were HER2-negative [5, 6, 9]. One tumor showed androgen receptor expression [8].

Differential diagnosis of mammary SC includes cutaneous SC and mammary lipid-rich carcinoma. Cutaneous SC can rarely involve the skin of the breast [19, 20] or the nipple [21]. The distinction between mammary and cutaneous SC can be made when there is no connection to the overlaying skin, both macroscopically and microscopically, or the tumor is completely surrounded by breast tissue [18]. Importantly, extraocular cutaneous SC can represent a manifestation of Muir-Torre syndrome (MTS), a phenotypic variant of Lynch syndrome (LS)/hereditary nonpolyposis colorectal cancer syndrome [22]. Muir-Torre syndrome/LS is caused by a germline mutation in one of the DNA mismatch repair genes resulting in nonfunctional protein, leading to microsatellite instability [22, 23]. Immunohistochemical detection of the DNA mismatch repair proteins (MMRP) can be used as a reliable screening method, as the loss of expression of a particular MMRP (most commonly MSH2 in MTS) generally correlates with the underlying germline mutation in the corresponding gene [22, 23]. All our cases showed retained immunohistochemical expression of MMRP. Kinkor et al. also did not find loss of MMRP expression in three cases of invasive ductal carcinoma with sebaceous differentiation [10]. Thus, so far, it seems that mammary carcinoma with sebaceous features is not associated with MTS/LS.

Lipid-rich (lipid-secreting) carcinoma is a rare special type of breast cancer. At least 90% of tumor

Table IV. Summary of clinicopathologic features of published cases of mammary sebaceous carcinoma

<table>
<thead>
<tr>
<th>Reference and year of publication</th>
<th>Clinical data</th>
<th>Staging data</th>
<th>ER, PR and HER2 status</th>
<th>Follow-up</th>
<th>Other findings / comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Van Bogaert et al. [1]; 1977</td>
<td>3 cases, gender not stated, age ≥ 33 to ≤ 76 years</td>
<td>tumor size: ≥ 1.2 to ≥ 3.5 cm; lymph node stage NA</td>
<td>NA</td>
<td>NA</td>
<td>all three cases originally described as a “sebaceous-type” lipid-secreting carcinoma</td>
</tr>
<tr>
<td>Mazzella et al. [3]; 1995</td>
<td>male, 55 years; left breast</td>
<td>tumor size: 5 cm; negative LN</td>
<td>ER+, PR+, HER2 NA</td>
<td>ANOD, 10 months</td>
<td>case originally described as infiltrating ductal carcinoma with “lipid-rich sebaceous-like” component</td>
</tr>
<tr>
<td>Tavassoli [4]; 1992</td>
<td>female, 46 years; right breast</td>
<td>tumor size: 7.5 cm; negative LN</td>
<td>ER–, PR+, HER2 NA</td>
<td>NA</td>
<td>squamoid morules; androgen receptor negative</td>
</tr>
<tr>
<td>Varga et al. [5]; 2000</td>
<td>female, 45 years; right breast</td>
<td>tumor size: 2.5 cm; negative LN</td>
<td>ER+, PR+, HER2–</td>
<td>AWD, 132 months; skin and bone MTS</td>
<td></td>
</tr>
<tr>
<td>Hisaoaka et al. [6]; 2006</td>
<td>female, 71 years; right breast</td>
<td>tumor size: 2 cm; one positive LN</td>
<td>ER+, PR+, HER2–</td>
<td>NA</td>
<td>androgen receptor negative</td>
</tr>
<tr>
<td>Moinfar [7]; 2007</td>
<td>female, 75 years; right breast</td>
<td>tumor size: NA; lymph node stage NA</td>
<td>ER–, PR–, HER2–</td>
<td>NA</td>
<td>squamous differentiation</td>
</tr>
<tr>
<td>Murakami et al. [8]; 2009</td>
<td>female, 50 years</td>
<td>tumor size: 2 cm; one positive LN</td>
<td>ER–, PR–, HER2 NA</td>
<td>ANOD, 24 months</td>
<td>androgen receptor positive</td>
</tr>
<tr>
<td>Ramljak et al. [9]; 2010</td>
<td>female, 85 years; left breast</td>
<td>tumor size: 7.5 cm; lymph node stage NA</td>
<td>ER–, PR–, HER2–</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

NA – not available; LN – lymph nodes; ANOD – alive with no evidence of disease; AWD – alive with disease; MTS – metastases
cells have abundant clear or vacuolated lipid-rich cytoplasm [12]. Interestingly, the first three cases of mammary SC were originally described as a variant (“sebaceous-type”) of lipid-secreting carcinoma [1]. In contrast to SC, which shows a compact lobulated solid growth pattern and finely vacuolated cells, lipid-rich carcinomas infiltrate like a regular invasive ductal carcinoma and vacuolization is much less conspicuous. The second cell population often present in the periphery of the lobules of the SC or squamous differentiation are absent in lipid-rich carcinomas [4]. In two studies, most cases of lipid-rich carcinoma were HER2-positive and ER/PR negative [24, 25].

In conclusion, we have described the clinicopathological features of four cases of mammary sebaceous carcinoma (sebaceous differentiation in at least 50% of tumor cells). Two of our patients had distant metastases and one patient died of the disease. This indicates that mammary SC is a potentially aggressive neoplasm. Most of the cases reported so far were ER/PR-positive, and hormonal therapy could represent a good therapeutic option. On the other hand, HER2 overexpression/amplification has not been reported so far. It seems that SC of the breast is unrelated to MTS/LS. More cases need to be investigated to better define the clinicopathological and prognostic features of this special type of breast cancer.

The following clinicians are acknowledged for providing the clinical follow-up: Radovan Barrila, MD, Department of Oncology and Radiotherapy, Štefan Kukura Hospital a.s., Michalovce, Slovakia; Libica Legiňová, MD, Department of Radiology, Louis Pasteur University Hospital, Košice, Slovakia; Bibiana Brezinová, MD, Department of Oncology, Hospital Trebišov a.s., Trebišov, Slovakia.

We are also grateful to RNDr. Lucia Lucia Fröhlichová, Department of Pathology, Louis Pasteur University Hospital, Košice, Slovakia, for performing the immunohistochemical studies.

The authors declare no conflict of interest.

References

23. Daum O, Beneš Z, Hadravský L, et al. Lynch syndrome in the Czech Republic. Mikulasske nam. 4 32600 Pilsen Czech Republic e-mail: svajdler@yahoo.com